Status:
COMPLETED
Iressa 2nd Line Phase III Study in Japan
Lead Sponsor:
AstraZeneca
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
In this study, among the patients with non-small cell lung cancer, those with metastasis or recurrence and previous treatment with chemotherapy will receive gefitinib or docetaxel, and we will compare...
Eligibility Criteria
Inclusion
- You are "histologically" or "cytologically" confirmed to have recurrent or metastatic NSCLC
- You have been treated with chemotherapy including platinums for NSCLC.
Exclusion
- You have received treatment for non-small lung cancer within 4 weeks before your participation in this study (except for specific therapies)
- You have or had any disease of acute lung injury, idiopathic pulmonary fibrosis, pulmonary pneumonia, or pneumoconiosis evident on the X-ray
- You have or had any disease of radiation pneumonia or drug-induced pneumonia, which requires treatment with corticosteroids
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2006
Estimated Enrollment :
484 Patients enrolled
Trial Details
Trial ID
NCT00252707
Start Date
September 1 2003
End Date
November 1 2006
Last Update
December 18 2007
Active Locations (40)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Nagoya, Aichi-ken, Japan
2
Research Site
Okazaki, Aichi-ken, Japan
3
Research Site
Hirosaki, Aomori, Japan
4
Research Site
Kashiwa, Chiba, Japan